IRLAB Therapeutics AB
Company Profile
Business description
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company’s current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
Contact
Arvid Wallgren Backe 20
Goteborg413 46
SWET: +46 317573800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
31
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,772.00 | 1.00 | -0.01% |
| CAC 40 | 7,665.91 | 25.64 | -0.33% |
| DAX 40 | 23,909.61 | 123.61 | -0.51% |
| Dow JONES (US) | 44,094.77 | 275.50 | 0.63% |
| FTSE 100 | 8,760.96 | 37.95 | -0.43% |
| HKSE | 24,072.28 | 211.87 | -0.87% |
| NASDAQ | 20,369.73 | 96.27 | 0.47% |
| Nikkei 225 | 39,986.33 | 501.06 | -1.24% |
| NZX 50 Index | 12,734.53 | 131.71 | 1.05% |
| S&P 500 | 6,204.95 | 31.88 | 0.52% |
| S&P/ASX 200 | 8,541.10 | 1.20 | -0.01% |
| SSE Composite Index | 3,444.43 | 20.20 | 0.59% |